Venetoclax combined with dose-reduced HAD as induction treatment for patients with de-novo acute myeloid leukemia

VernacularTitle:维奈克拉联合减低剂量HAD方案诱导治疗急性髓系白血病的疗效观察
Author: Zhangsong YAN ¹ ; Yang LI ; Bin ZHANG ; Jinsong HE ; Jiesi LI ; Shuning WEI ; Qi WANG ; Qiuling LI ; Kaiqi LIU ; Yingchang MI
Author Information

1. 中国医学科学院血液病医院(中国医学科学院血液学研究所)，血液与健康国家重点实验室，国家血液系统疾病临床医学研究中心，细胞生态海河实验室，天津　300020
From: Chinese Journal of Hematology 2024;45(4):387-390
CountryChina
Language:Chinese
Abstract: The efficacy and safety of venetoclax combined with reduced dose HAD regimen in the treatment of newly diagnosed acute myeloid leukemia (AML) was investigated. From May 2022 to January 2023, a total of 25 patients with newly diagnosed AML were treated with venetoclax combined with reduced-dose HAD regimen as induction therapy. Accoding to the 2017 ELN recommendations, 13 (52.0%) in favoable, 3 (12.0%) in intemediate, and 9 (36.0%) in adverse. The ORR (CR rate+PR rate) was 88.0%, and the CR rate was 84.0%. By May 30, 2023, with a median follow-up of 9 months, 1 year overall survival, event-free survival, and relapse-free survival were 100%, 94.7%, and 94.7%, respectively. All patients received 1-5 cycles of consolidation therapy and two median cycles. Treatment with venetoclax and reduced dose of HAD regimen in the treatment of patients with newly diagnosed AML was high effective and safe.